Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.54 |
| ▸ | LPL | P06858 | 6/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13325342 | 1.00 | LIPG (0.54) | LIPGLPLTRPV1MGLLGPR35 | |
| SCHEMBL1651743 | 1.00 | LIPG (0.54) | LIPGLPLTRPV1MGLLGPR35 | |
| SCHEMBL14359451 | 0.92 | LIPG (0.47) | LIPGLPLTRPV1MGLLGPR35 | |
| SCHEMBL4270833 | 0.79 | LIPG (0.41) | LIPGLPLTRPV1MGLLTYR | |
| SCHEMBL1650895 | 0.78 | LIPG (0.43) | LIPGLPLTRPV1MGLLGPR35 | |
| SCHEMBL526232 | 0.77 | LIPG (0.39) | LIPGLPLTRPV1MGLLGPR35 | |
| SCHEMBL2970195 | 0.77 | LIPG (0.46) | LIPGLPLGPR35TYRTP53 | |
| SCHEMBL2966300 | 0.77 | LIPG (0.46) | LIPGLPLGPR35TYRTP53 | |
| SCHEMBL2959056 | 0.77 | LIPG (0.46) | LIPGLPLGPR35TYRTP53 | |
| SCHEMBL10414775 | 0.77 | TYR (0.49) | LIPGTYRTP53CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SunVax mRNA Therapeutics Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SunVax mRNA Therapeutics Inc. (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | PHOSPHO1, SGMS1, PLIN3 | LIPG 24/4885LPL 169/4885TRPV1 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.